Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors